SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection, offering comprehensive information for improved patient management. SpeeDx has a suite of products, covering a range of STDs and other infectious diseases, including respiratory viruses.

SpeeDx’s ResistancePlus™ MG is a multiplex qPCR kit – powered by proprietary PlexZyme™ and PlexPrime™ technologies – offering enhanced mutation discrimination with high multiplexing capabilities, for more streamlined infectious disease management. ResistancePlus MG is the first assay available on the market that can detect both Mycoplasma genitalium and mutations in the 23S rRNA gene of the bacteria that have been shown to confer resistance to azithromycin, a commonly prescribed macrolide-based antibiotic.

The availability of this assay across Europe will be a welcome tool for clinicians responding to the latest European guidelines for management of non-gonococcal urethritis (NGU) that recommend screening for macrolide resistance when testing for M. genitalium.